Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC
The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.
COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC
The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.
Approaches to Dosing TKIs in Patients with Advanced RCC
Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.
Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens
The panel discusses which patients they would consider switching between immunotherapy combination treatments.
Approaches to the Frontline Treatment of Advanced Kidney Cancer
Experts summarize their most common frontline treatment approaches to advanced RCC.
Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy
Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.
Impact of the CLEAR Trial Data Updates in Clinical Practice
The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings
Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes
Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.
Interpreting Adjuvant Therapy Trial Results in Advanced RCC
Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.
Advanced Renal Cell Carcinoma: Nuancing Triplet Therapy Trial Results
Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.
Clinical Trial Data in Relapsed/Refractory Renal Cell Carcinoma
Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.
First-Line Clinical Trial Data in Advanced Renal Cell Carcinoma
A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.
Renal Cell Carcinoma: Overlapping Toxicity in TKI/IO Combination Therapy
Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.
Adverse Event Management in Patients With Advanced RCC
Expert perspectives on the most common adverse events seen while managing advanced renal cell carcinoma, followed by advice on how best to manage these and counsel patients.
Factors in Selecting First-Line Therapy for Patients With Advanced RCC
Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Advanced Renal Cell Carcinoma: An Evolving Treatment Armamentarium
Expert oncologists Matthew Campbell, MD, MS, and Brian Rini, MD, open their discussion on advanced renal cell carcinoma management by defining cornerstone treatment approaches.
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Renal Cell Carcinoma: Future Directions in Care
Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.
Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab
Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.
Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?
Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.
Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy
Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
2 Clarke Drive Cranbury, NJ 08512